摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-苄基-4-(环丙基甲基)氨基哌啶 | 387358-47-6

中文名称
N-苄基-4-(环丙基甲基)氨基哌啶
中文别名
1-苄基-N-环丙基哌啶-4-胺
英文名称
1-benzyl-N-cyclopropylpiperidin-4-amine
英文别名
——
N-苄基-4-(环丙基甲基)氨基哌啶化学式
CAS
387358-47-6
化学式
C15H22N2
mdl
MFCD01308091
分子量
230.35
InChiKey
GARBAAKWXMLSOF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    118℃/0.1mm
  • 密度:
    1.06±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    15.3
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933399090

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    N-4-piperidinyl compounds as ccr5 modulators
    摘要:
    本发明提供一个化合物,其化学式为(1):其中R1,R2,R3,R3a,R4,R4a,R5和R6被定义;或其药学上可接受的盐或溶剂;包含这些化合物的组合物,制备这些化合物的过程以及它们作为趋化因子活性调节剂(特别是CCR5活性调节剂)的用途。
    公开号:
    US20040110952A1
  • 作为产物:
    参考文献:
    名称:
    N-4-piperidinyl compounds as ccr5 modulators
    摘要:
    本发明提供一个化合物,其化学式为(1):其中R1,R2,R3,R3a,R4,R4a,R5和R6被定义;或其药学上可接受的盐或溶剂;包含这些化合物的组合物,制备这些化合物的过程以及它们作为趋化因子活性调节剂(特别是CCR5活性调节剂)的用途。
    公开号:
    US20040110952A1
点击查看最新优质反应信息

文献信息

  • [EN] 1,4 DI SUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS<br/>[FR] DÉRIVÉS 1,4 DI SUBSTITUÉS PYROLIDINE-3-YL-AMINE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
    申请人:PROSIDION LTD
    公开号:WO2012066077A1
    公开(公告)日:2012-05-24
    Therapeutic compounds are disclosed having the general formula (1) that are useful for the treatment of metabolic disorders, including type II diabetes.The compounds have activity as agonists of GPR1 19. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.
    揭示了具有一般式(1)的治疗化合物,可用于治疗代谢性疾病,包括2型糖尿病。这些化合物具有作为GPR1 19激动剂的活性。具有式(la)的立体化学构型的化合物也可能表现出DPP-IV抑制活性。
  • [EN] 1,4 DISUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS<br/>[FR] DÉRIVÉS DE PYROLIDIN-3-YL-AMINE 1,4 DISUBSTITUÉE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
    申请人:PROSIDION LTD
    公开号:WO2013026587A1
    公开(公告)日:2013-02-28
    Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR1 19. Compounds having stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.
    揭示了具有一般式(I)的治疗化合物,可用于治疗代谢性疾病,包括2型糖尿病。这些化合物具有作为GPR1 19激动剂的活性。具有一般式(la)立体化学的化合物也可能表现出DPP-IV抑制活性。
  • 4-phenylsulfonamidopiperidines as calcium channel blockers
    申请人:Benjamin Elfrida R.
    公开号:US20090105249A1
    公开(公告)日:2009-04-23
    The invention relates to piperidinyl compounds of Formula (I): or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R 1 -R 3 and Z are defined as set forth in the specification. The invention is also directed to an assay useful for identifying such compounds as N-type calcium channel modulators or blockers. The invention is also directed to the compounds of Formula (I) and compounds identified by the above assay, and the use of such compounds to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.
    该发明涉及式(I)的哌啶基化合物:或其药用可接受的盐、前药或溶剂,其中R1-R3和Z如规范中所述。该发明还涉及一种用于识别此类化合物作为N-型钙通道调节剂或阻断剂的测定方法。该发明还涉及式(I)的化合物和通过上述测定方法鉴定的化合物,以及使用这些化合物来治疗、预防或改善对钙通道阻断作出反应的疾病,尤其是N-型钙通道。本发明的化合物特别适用于治疗疼痛。
  • Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels
    申请人:Chen Zhengming
    公开号:US20100022595A1
    公开(公告)日:2010-01-28
    The invention relates to piperidinyl and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R 1 -R 3 , Z and q are defined as set forth in the specification. The invention is also directed to the use compounds of Formula (I) to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.
    本发明涉及公式(I)的哌啶基和六氢唑啉基化合物及其药学上可接受的盐,前药或溶剂,其中R1-R3,Z和q如规范中所述。本发明还针对使用公式(I)的化合物治疗、预防或改善对钙通道阻滞有响应的疾病,特别是N型钙通道。本发明的化合物特别适用于治疗疼痛。
  • Benzenesulfonamide Compounds and the Use Thereof
    申请人:Matsumura Akira
    公开号:US20090306136A1
    公开(公告)日:2009-12-10
    The invention relates to azetidinyl, pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R 1 -R 3 , Z, p and q are defined as set forth in the specification. The invention is also directed to the use compounds of Formula (I) to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.
    本发明涉及式(I)的吡咯烷基,吡咯啉基,哌啶基和六氢氮杂环基化合物,以及其药学上可接受的盐,前药或溶剂化物,其中R1-R3,Z,p和q如规范所述。本发明还涉及使用式(I)的化合物治疗,预防或改善对钙通道阻滞有反应的疾病,特别是N型钙通道。本发明的化合物特别适用于治疗疼痛。
查看更多